UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

Rheumatology (Oxford, England), 2010-02, Vol.49 (2), p.295-307

2010

Volltextzugriff (PDF)

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

Rheumatology (Oxford, England), 2011-03, Vol.50 (3), p.518-531

2011

Volltextzugriff (PDF)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Biologics, 2021-01, Vol.15, p.343-352

2021

Volltextzugriff (PDF)

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2019-11, Vol.71 (11), p.1788-1800

2019

Volltextzugriff (PDF)

Contemporary treatment principles for early rheumatoid arthritis: a consensus statement

Rheumatology (Oxford, England), 2009-07, Vol.48 (7), p.765-772

2009

Volltextzugriff (PDF)

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Rheumatology and therapy., 2017-06, Vol.4 (1), p.85-96

2017

Volltextzugriff (PDF)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials

Rheumatic & musculoskeletal diseases open, 2022-03, Vol.8 (1), p.e002049

2022

Volltextzugriff (PDF)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

Rheumatic & musculoskeletal diseases open, 2022-06, Vol.8 (2), p.e002286

2022

Volltextzugriff (PDF)

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases–an observational study

PloS one, 2024-06, Vol.19 (6), p.e0300624

2024

Volltextzugriff (PDF)

Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis

Rheumatology (Oxford, England), 2020-09, Vol.59 (9), p.2217-2225

2020

Volltextzugriff (PDF)

Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries

Rheumatology (Oxford, England), 2012-02, Vol.51 (2), p.393-396

2012

Volltextzugriff (PDF)

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance

Clinical rheumatology, 2012-06, Vol.31 (6), p.1005-1012

2012

Volltextzugriff (PDF)

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Rheumatology and therapy., 2017-06, Vol.4 (1), p.97-97

2017

Volltextzugriff (PDF)

Immune checkpoint inhibitor‐induced lymphocytic fasciitis

Internal medicine journal, 2018-12, Vol.48 (12), p.1550-1552

2018

Volltextzugriff (PDF)

Time to flare in giant cell arteritis and polymyalgia rheumatica: analysis from a single‐centre Australian practice

Internal medicine journal, 2024-05, Vol.54 (5), p.838-839

2024

Volltextzugriff (PDF)

Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review

Advances in therapy, 2022-01, Vol.39 (1), p.75-93

2022

Volltextzugriff (PDF)

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

Annals of the rheumatic diseases, 2012-12, Vol.71 (12), p.1950-1954

2012

Volltextzugriff (PDF)

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

Postgraduate Medical Journal, 2007-04, Vol.83 (978), p.251-260

2007

Volltextzugriff (PDF)

Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Arthritis research & therapy, 2016-12, Vol.18 (1), p.302-302, Article 302

2016

Volltextzugriff (PDF)

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review

Clinical rheumatology, 2011-11, Vol.30 (11), p.1471-1474

2011

Volltextzugriff (PDF)

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial

Rheumatology (Oxford, England), 2018-01, Vol.57 (1), p.84-91

2018

Volltextzugriff (PDF)

TNF antagonists and shingles: is vaccination advisable?

Annals of the rheumatic diseases, 2013-05, Vol.72 (5), p.e1-e1

2013

Volltextzugriff (PDF)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Rheumatic & musculoskeletal diseases open, 2022-07, Vol.8 (2), p.e002280

2022

Volltextzugriff (PDF)

Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort

Clinical rheumatology, 2014-05, Vol.33 (5), p.609-614

2014

Volltextzugriff (PDF)

Orbital Cellulitis in a Patient Receiving Infliximab for Ankylosing Spondylitis

American journal of ophthalmology, 2006-04, Vol.141 (4), p.767-769

2006

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(92)
Science & Technology
(89)
Life Sciences & Biomedicine
(88)
Rheumatology
(67)
Arthritis, Rheumatoid - Drug Therapy
(46)
Rheumatoid Arthritis
(46)
Female
(38)
Antirheumatic Agents - Therapeutic Use
(37)
Middle Aged
(32)
Adult
(30)
Male
(30)
Biological And Medical Sciences
(26)
Medical Sciences
(26)
Treatment Outcome
(26)
Aged
(24)
Medicine
(21)
Medicine & Public Health
(21)
Antirheumatic Agents - Adverse Effects
(19)
Diseases Of The Osteoarticular System
(18)
Inflammatory Joint Diseases
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

Contemporary treatment principles for early rheumatoid arthritis: a consensus statement

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases–an observational study

Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis

Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study

Immune checkpoint inhibitor‐induced lymphocytic fasciitis

Time to flare in giant cell arteritis and polymyalgia rheumatica: analysis from a single‐centre Australian practice

Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial

TNF antagonists and shingles: is vaccination advisable?

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort

Orbital Cellulitis in a Patient Receiving Infliximab for Ankylosing Spondylitis

Suchergebnisse filtern